Core Viewpoint - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant, which is intended to treat hypertension secondary to hypercortisolism [1][2]. Company Summary - On December 31, 2025, Corcept announced it received a Complete Response Letter (CRL) from the FDA, which denied the approval of relacorilant, citing the need for additional evidence of effectiveness despite acknowledging previous trial results [2]. - The stock price of Corcept fell by $31.42 (44.76%) to open at $38.78 per share on the same day, marking a new 52-week low and reaching levels not seen since September 2024 [3].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Corcept Therapeutics Incorporated for possible violations of federal securities laws and unlawful business practices following a significant stock price drop after an FDA response regarding a new drug application [1][2]. Investigation Details - On December 31, 2025, Corcept announced that the FDA issued a Complete Response Letter regarding its New Drug Application for relacorilant, which is intended for treating hypertension secondary to hypercortisolism. The FDA acknowledged that Corcept's pivotal GRACE trial met its primary endpoint but required additional evidence of effectiveness, leading to a stock price decline of $35.40 per share, or 50.42%, closing at $34.80 [2]. Next Steps - Investors who purchased or acquired Corcept shares and experienced losses are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims. There is no cost or obligation for this consultation [3]. About Bragar Eagel & Squire, P.C. - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with a focus on representing individual and institutional investors in various types of litigation, including securities and commercial cases. The firm operates nationwide and handles cases in both federal and state courts [4].

Core Insights - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant [1] - The FDA's complete response letter (CRL) indicated that while previous drug trials were acknowledged, additional evidence of effectiveness was required for a favorable benefit-risk assessment [2] - Following the FDA's announcement, Corcept's stock price experienced a significant drop of $31.42, representing a 44.76% decrease, opening at $38.78 per share [2] Company Performance - The stock price decline marks a new 52-week low for Corcept, reaching levels not seen since September 2024 [3] - The investigation by Levi & Korsinsky LLP aims to assist investors who may have suffered losses in Corcept's securities [3] Legal Context - Levi & Korsinsky LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm is recognized as one of the top securities litigation firms in the United States, with extensive expertise in complex securities cases [4]

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ: CORT) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CORCEPT THERAPEUTICS INCORPORATED (CORT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER. ...

Core Viewpoint - A class action lawsuit has been filed against BlackRock TCP Capital Corp. (TCPC) for securities fraud, alleging that the company made materially false statements and failed to disclose adverse facts about its business and operations during the class period from November 6, 2024, to January 23, 2026 [1] Financial Performance - The company's portfolio significantly weakened in the fiscal year 2024, with the number of portfolio companies on non-accrual status more than doubling, leading to a 289% increase in debt investments on non-accrual status at cost, rising from 3.7% to 14.4% of the portfolio [1] - The net asset value (NAV) fell by 22.44% year over year to $9.23 per share, with total losses (realized and unrealized) ballooning to $194.9 million, a 186% increase year over year, largely due to a newly added $72.3 million net unrealized loss in the fourth quarter [1] - On January 23, 2026, the company disclosed that its NAV per share as of December 31, 2025, was between $7.05 and $7.09, representing a 19% decrease from the previous quarter and a 23.4% decrease from the prior year [1] Allegations of Misconduct - The lawsuit alleges that the defendants made materially false and misleading statements and failed to disclose critical information regarding the company's investments, portfolio restructuring efforts, and the true state of unrealized losses and NAV [1] - Specific allegations include the failure to timely and appropriately value investments, ineffective portfolio restructuring, understated unrealized losses, and overstated NAV, leading to misleading positive statements about the company's business prospects [1]

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ: CORT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CORCEPT THERAPEUTICS INCORPORATED (CORT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On December 31, 2025, Corcept announc. ...

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] ...

Core Viewpoint - Corcept Therapeutics Inc. is under investigation for potentially misleading investors regarding the efficacy and commercial prospects of its drug relacorilant, following warnings from the FDA not to submit its application for approval [1][2][4]. Group 1: Company Performance and Market Impact - Corcept's shares have declined significantly, resulting in a loss of approximately $3.2 billion in market capitalization since December 2025 [2]. - The company had previously projected that its hypercortisolism business could grow from $3 billion to $5 billion in annual revenue within three to five years [3]. Group 2: Regulatory Communications and Investor Relations - On December 31, 2025, Corcept received a complete response letter (CRL) from the FDA, indicating that the agency could not reach a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness [4]. - A corrected CRL issued on January 28, 2026, revealed that the FDA had warned Corcept multiple times against submitting its application, contradicting the company's earlier statements about its communications with regulators [4]. Group 3: Legal Investigation - Hagens Berman is expanding its investigation to determine if Corcept misled investors regarding its communications with the FDA, as well as the efficacy and safety of relacorilant [5].

Core Viewpoint - Corcept Therapeutics faces significant setbacks regarding its proposed treatment for hypercortisolism, relacorilant, following warnings from the FDA not to submit its drug application, leading to a sharp decline in share price [1][2]. Company Developments - On January 30, 2026, Corcept shares dropped by $7.81, or 17%, after reports of FDA warnings against submitting the drug application [1]. - The company's market capitalization has decreased by $3.2 billion since December 30, 2025, following the receipt of a complete response letter (CRL) from the FDA [4]. FDA Communications - The FDA had previously issued a CRL indicating that it could not arrive at a favorable benefit-risk assessment for relacorilant without additional evidence of effectiveness [3]. - A corrected CRL dated January 28 revealed that the FDA had warned Corcept on multiple occasions about significant review issues if the application was submitted [3]. Investor Concerns - Hagens Berman, a law firm, is investigating whether Corcept misled investors regarding relacorilant's efficacy and the company's communications with the FDA [2][4]. - The firm is also analyzing if Corcept overstated its commercial and growth prospects for the hypercortisolism business, which was projected to grow from $3 billion to $5 billion in annual revenues within three to five years [3].

BOSTON, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Berman Tabacco, a national law firm representing investors, announces that it is investigating potential securities law violations by Corcept Therapeutics Incorporated (Nasdaq: CORT) (“Corcept” or the “Company”), a company based in Redwood City, California. About the Investigation On December 31, 2025, Corcept issued a press release announcing that “U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New D ...